AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B
Bio Pharma Dive
DECEMBER 12, 2023
The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Bio Pharma Dive
DECEMBER 12, 2023
The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.
Bio Pharma Dive
JANUARY 5, 2022
The pharma company, already partnered with BioNTech on vaccines for COVID-19 and influenza, will pay $225 million upfront to further expand its work with the German biotech.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 1, 2024
Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's (..)
BioSpace
SEPTEMBER 26, 2023
The COVID-19 pandemic highlighted a need for local production of vaccines. Now, German pharma company BioNTech has said it will start manufacturing vaccines in Africa.
World of DTC Marketing
DECEMBER 9, 2020
Pfizer is having supplier issues, some people who received the vaccine are reporting side effects like Bell’s Palsy. In the meantime this administration is patting itself on the back for the quick development of vaccines. What assurances does the public have that every dose of vaccine is made to the highest quality standards?
World of DTC Marketing
JULY 20, 2021
29 percent of Americans said they were unlikely to get vaccinated — up from 24 percent three months earlier. Most workers do not want their own employer to require vaccination, including the vast majority of unvaccinated workers (92%). Yet even as evidence grows that vaccines are safe and effective, resistance to them is also growing.
BioSpace
APRIL 18, 2024
French healthcare and pharma company Sanofi will terminate an undisclosed number of positions in its U.S. vaccines commercial unit in an effort to streamline the strategic sales structure.
World of DTC Marketing
JANUARY 8, 2021
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. So far the winners are Pfizer and Moderna.
XTalks
MAY 29, 2024
The top ten pharma companies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 The top big pharma players have remained relatively consistent in their market positions over the past several years. Here is a look at the top ten pharma companies in 2024 based on 2023 revenue.
World of DTC Marketing
DECEMBER 7, 2021
LEAD IN: Pharma companies are a business and have the right to make money but at what cost and how much is enough? The world’s makers of Covid-19 vaccines—saw over $10 billion in new wealth, with the Moderna’s CEO alone adding over $800 million to his fortune. Is this acceptable?
World of DTC Marketing
JULY 28, 2020
QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. Moderna, a 10-year-old vaccine developer based in Cambridge, Mass.,
World of DTC Marketing
MARCH 25, 2021
SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The vaccines are already poised to be some of the most lucrative drugs of all time.
World of DTC Marketing
MAY 21, 2021
IT’S FRIDAY: The Biden administration’s decision to support a temporary waiver of Covid-19 vaccine patents prompted instant and false outrage in pharma. Pharma is afraid the move could compromise future drug profits, so they need to fight hard now to ensure it doesn’t happen again.
Bio Pharma Dive
SEPTEMBER 2, 2021
The pharma company is in a tight race with rivals, including GSK, to become the first with an approved shot for the infectious disease.
World of DTC Marketing
APRIL 2, 2021
QUICK READ: Pfizer is already positioning their Covid vaccine as a yearly maintenance shot. Make no mistake; the drug companies will make a lot of money from these vaccines while they continue to hide profits offshore. ( New York Times) If you listen to the stated intentions of vaccine producers.
BioSpace
OCTOBER 28, 2020
BioSpace provides an up-to-date overview of these deals and the projected COVID-19 vaccine doses each company plans to have within the next couple of years.
World of DTC Marketing
SEPTEMBER 7, 2020
IN SHORT: It may be too late for pharma to persuade the public that any COVID-19 vaccine is safe and effective as the FDA continues to be a political baseball in play. It’s now being reported that up to one-third of people may not get a COVID-19 vaccination when one become available. Now comes the power of social media.
World of DTC Marketing
JULY 22, 2020
QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?” health officials agreed to pay $1.95
Medical Xpress
MARCH 13, 2023
Six mobile vaccine production units by German pharma company BioNTech arrived in Rwanda on Monday, the first such shipments to Africa as the continent seeks to boost mRNA vaccine manufacturing.
World of DTC Marketing
MARCH 15, 2021
SUMMARY : Big pharma is a big business, and nothing motivates big companies more than the potential to earn a lot of money on new products. Pfizer, alone, is estimated to earn about $15 billion for their vaccine, and they had absolutely nothing to do with Operation Warp Speed. There’s a lot of money in COVID vaccines.
World of DTC Marketing
NOVEMBER 12, 2020
Pfizer did not take government money to develop a COVID vaccine and said the release of preliminary vaccine data was based on receiving the data on Monday. According to JAMA , “between January 2010 and June 2020, the FDA approved 21 vaccines, most commonly for influenza (5 [23.8%]) and meningococcus (5 [23.8%]).
BioPharma Reporter
NOVEMBER 18, 2020
While governments are now getting ready to ensure large-scale, equitable access and distribution of a COVID-19 vaccine, concern about vaccine hesitancy is growing worldwide. The COVID-19 pandemic is expected to continue to impose enormous burdens on societies and economies globally.
World of DTC Marketing
FEBRUARY 28, 2021
SUMMARY: Pharma companies, like J&J, have received criticism for engaging in illegal activities, such as providing kickbacks and bribes, knowingly shipping adulterated or contaminated drugs to pharmacies, and marketing drugs for unapproved uses. Can a COVID-19 vaccine approval suddenly erase that? billion in penalties.
World of DTC Marketing
AUGUST 3, 2020
QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. Personally I would want to know as much as I can before I ask for the vaccine but I also know that greed can make people do stupid things and there is a lot of money at stake here.
World of DTC Marketing
JULY 26, 2021
There are many reasons why people aren’t getting vaccinated. Pharma companies should ensure that product content also contains health information to address chronic conditions. Until we have more data to really understand why people are getting vaccinated against COVID, we shouldn’t fall into the trap of blame.
BioPharma Reporter
FEBRUARY 2, 2021
Rows about vaccine supply and threats of export blocks donât do anything to bring us closer to ending the COVID-19 pandemic, say campaigners pushing for vaccine equity on a global level.
BioPharma Reporter
MARCH 23, 2021
The pharma company and the CDC are recommending that adults continue routine vaccination during the COVID-19 pandemic to reduce future vaccine-preventable disease (VPD) outbreaks and overall strain on the healthcare system.
Drug Discovery World
DECEMBER 7, 2022
We are excited to open up the waitlist for the next stage, and encourage people from other backgrounds to get involved, including our tech company members.” . The programme is like a vaccine – we expose leaders to trial situations to understand the root causes of how inequality manifests in the workplace and to uncover unconscious biases.
Pharmaceutical Technology
NOVEMBER 15, 2022
When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. This also has clear advantages in healthcare settings, particularly when it comes to vaccines. In general, a prefilled syringe is clearly preferred for vaccines.”. A new challenge .
pharmaphorum
APRIL 19, 2021
The UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its COVID-19 jab there, according to the head of the country’s Vaccines Taskforce. . It is really important and we have seen a lot of pharma companies interested in the UK. Speed is everything in clinical development.
The Pharma Data
DECEMBER 20, 2020
UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.
pharmaphorum
FEBRUARY 9, 2022
In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front.
Pharmaceutical Commerce
JULY 7, 2023
Pharma company will produce seven vaccines, as nation aims to strengthen status as a life sciences hub.
pharmaphorum
NOVEMBER 29, 2021
The UK’s Vaccines Manufacturing and Innovation Centre (VMIC) – unveiled with fanfare by the government in 2018 – is rumoured to be up for sale. It was billed at the time as a key tool to accelerate the development of new and innovative vaccines to combat some of the world’s most prevalent diseases, from discovery to licensed product.
XTalks
SEPTEMBER 5, 2023
Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?
pharmaphorum
DECEMBER 10, 2020
The European Medicines Agency (EMA) says it suffered a cyberattack, with documents relating to a Pfizer and BioNTech’s COVID-19 vaccine accessed. Shortly after however BioNTech confirmed that documents submitted as part of its marketing application for coronavirus vaccine BNT-162b had been accessed by the hackers.
pharmaphorum
OCTOBER 7, 2021
Moderna has said it plans to invest $500 million in a new facility for manufacturing mRNA vaccines in Africa, and has kicked off a search to find a suitable country and location. of Africans have been fully vaccinated against COVID-19, and just 15 African nations have met the agency’s objective of 10% coverage.
pharmaphorum
MARCH 24, 2021
The Prime Minister reportedly told Conservative backbench MPs on a Zoom call that “capitalism” and “greed” was behind the success of the UK’s COVID-19 vaccination programme, before backtracking after realising he had made a blunder and telling attendees to forget the comments. " But he’s wrong.
pharmaphorum
AUGUST 23, 2021
The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.
BioPharma Reporter
JANUARY 28, 2022
Contract development and manufacturing organization (CDMO), Recipharm, says it has inked a deal with a top 10 big pharma company to support vaccine manufacturing from its facility in Kaysersberg, France.
pharmaphorum
DECEMBER 16, 2022
Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.
World of DTC Marketing
NOVEMBER 27, 2020
SUMMARY: Business by press release has made pharma executives a lot of money but we still haven’t seen any over reviewed data on COVID 19 vaccines. The American Nurses Association, a national professional organization, said one-third of its members do not intend to take the vaccine, and an additional third are undecided.
BioPharma Reporter
JANUARY 12, 2021
The European Commission had held discussions with French pharma company, Valneva, with a view to securing up to 60 million doses of its inactivated virus COVID-19 vaccine, VLA2001.
World of DTC Marketing
SEPTEMBER 28, 2020
J&J’s COVID vaccine is being promoted by the media to have a 98% immune system response. Will it lead to an early approval with limited testing or will J&J ensure the vaccine goes thru thorough testing? What exactly does that mean is still unknown as more testing is needed but will that vaccine get thorough testing?
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content